<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7139252\results\search\drugs\results.xml">
  <result pre="one minute. In contrast, other biocidal agents, such as 0.05–0.2%" exact="benzalkonium chloride," post="or 0.02% chlorhexidine digluconate, are less effective [24]. The"/>
  <result pre="other biocidal agents, such as 0.05–0.2% benzalkonium chloride, or 0.02%" exact="chlorhexidine" post="digluconate, are less effective [24]. The avoidance of these"/>
  <result pre="the virus entry into the host cells 5.2.1 Chloroquine and" exact="hydroxychloroquine" post="These viral entry blockages include chloroquine, hydroxychloroquine umifenovir, and"/>
  <result pre="5.2.1 Chloroquine and hydroxychloroquine These viral entry blockages include chloroquine," exact="hydroxychloroquine" post="umifenovir, and interferon [112]. A cell line study reported"/>
  <result pre="umifenovir, and interferon [112]. A cell line study reported that" exact="chloroquine" post="significantly decreased the human coronavirus-229E replication at a lower"/>
  <result pre="the clinical safety profiles, that justify future clinical research of" exact="chloroquine" post="and hydroxychloroquine in patients with COVID-19 [114]. There are"/>
  <result pre="safety profiles, that justify future clinical research of chloroquine and" exact="hydroxychloroquine" post="in patients with COVID-19 [114]. There are currently several"/>
  <result pre="with COVID-19 [114]. There are currently several clinical trials of" exact="chloroquine" post="for COVID-19, either as monotherapy or in combination with"/>
  <result pre="as monotherapy or in combination with other medications such as" exact="azithromycin" post="[112]. A non-randomized clinical trial reported the reduction of"/>
  <result pre="report the critical clinical outcomes, including death [115]. Chloroquine and" exact="hydroxychloroquine" post="are the immunomodulatory drugs with potential antiviral effects. However,"/>
  <result pre="medications. It is still premature to conclude the role of" exact="chloroquine" post="and hydroxychloroquine in COVID-19, while several clinical trials are"/>
  <result pre="is still premature to conclude the role of chloroquine and" exact="hydroxychloroquine" post="in COVID-19, while several clinical trials are on their"/>
  <result pre="pathway, including Janus-associated kinase (JAK) inhibitors through baricitinib, ruxolitinib, and" exact="imatinib" post="[119,120]. Currently, some of these drugs are being tested"/>
  <result pre="of HIV infection [137]. The cytochrome P450 inhibitory effects of" exact="ritonavir" post="prolonged the half-life of Lopinavir and extended its protease"/>
  <result pre="uses in combination with other cytochrome P450 inhibitors, such as" exact="ritonavir" post="or cobicistat, for the treatment of HIV infection [143]."/>
  <result pre="for the efficacy against COVID-19 [112]. 5.4.3 Viperin, emodin, and" exact="promazine" post="There was the in-vitro evidence of inhibitory action on"/>
  <result pre="Res.77200815015218055026 114CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.005(Epub ahead of"/>
  <result pre="treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.005(Epub ahead of print) 115GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.DupontH.HonoréS.ColsonP.ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="treatment of hemorrhagic fever virus infectionsChem. Asian J.1420193962396831389664 133WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="(2019-nCoV)Nat. Rev. Drug Discov.19202014915032127666 135WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC.PanJ.ZhengJ.LuB.GuoL.Comparative effectiveness of combined favipiravir and" exact="oseltamivir" post="therapy versus oseltamivir monotherapy in critically ill patients with"/>
  <result pre="Discov.19202014915032127666 135WangY.FanG.SalamA.HorbyP.HaydenF.G.ChenC.PanJ.ZhengJ.LuB.GuoL.Comparative effectiveness of combined favipiravir and oseltamivir therapy versus" exact="oseltamivir" post="monotherapy in critically ill patients with influenza virus infectionJ."/>
  <result pre="SARS: initial virological and clinical findingsThorax59200425225610.1136/thorax.2003.01265814985565 141KimU.J.WonE.-J.KeeS.-J.JungS.-I.JangH.-C.Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-α for Middle East respiratory syndromeAntivir. Ther.21201645545910.3851/IMP300226492219 142ArabiY.M.AsiriA.Y.AssiriA.M.JokhdarH.A."/>
  <result pre="for a recursive two-stage group sequential randomized controlled trialTrials212020810.1186/s13063-019-3846-x31900204 143BalayanT.HorvathH.RutherfordG.W.Ritonavir-boosted" exact="darunavir" post="plus two nucleoside reverse transcriptase inhibitors versus other regimens"/>
 </snippets>
</snippetsTree>
